Evaxion A/S (EVAX) vs IGC Pharma (IGC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IGC Pharma (IGC) has outperformed Evaxion A/S (EVAX) over the past year, losing 32.2% versus a loss of 51.5%. Over five years, IGC leads with a -80.5% price change compared with -99.2% for EVAX. IGC Pharma is the larger company by market cap ($29.5 million vs $27.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVAX | IGC |
|---|---|---|
| Share price | $3.05 | $0.2849 |
| Market cap | $27.52M | $29.45M |
| 1-day change | -2.87% | +1.75% |
| YTD return | -36.06% | +1.75% |
| 1-year return | -51.51% | -32.17% |
| 5-year return | -99.23% | -80.49% |
| EPS (TTM) | $-1.00 | $-0.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.15 | $0.45 |
| 52-week low | $2.77 | $0.24 |
| Distance from 52-week high | -74.90% | -36.69% |
| Analyst consensus | none | none |
| Avg. price target upside | +268.85% | +2006.00% |
| Average volume | 200.14K | 704.91K |
| Shares outstanding | 9.02M | 103.38M |
| Employees | 46 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IGC has outperformed EVAX by 19.3 percentage points over the past year.
About Evaxion A/S
EVAX stock →Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
About IGC Pharma
IGC stock →IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
EVAX vs IGC FAQ
Which is bigger, Evaxion A/S or IGC Pharma?
IGC Pharma (IGC) is larger, with a market capitalization of $29.45M compared with $27.52M for Evaxion A/S (EVAX).
Which stock has performed better over the past year, EVAX or IGC?
IGC returned -32.17% over the past 12 months, compared with -51.51% for EVAX (price return, excluding dividends). Past performance does not predict future results.
Are Evaxion A/S and IGC Pharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Evaxion A/S and Biotechnology: Pharmaceutical Preparations for IGC Pharma.